Just a moment, the page is loading...

Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis








Comparative safety and effectiveness of cognitive enhancers for Alzheimer's dementia: a systematic review and individual patient data network meta-analysis


Andrea C. Tricco


Knowledge Translation Program, Li Ka Shing Knowledge Institute, St. Michael's Hospital


ACT is funded by a Tier 2 Canada Research Chair in Knowledge Synthesis. AAV is funded by the Canadian Institutes of Health Research (CIHR) Banting Postdoctoral Fellowship Program. SES is funded by a Tier 1 Canada Research Chair in Knowledge Translation. This research is funded by the CIHR Drug Safety and Effectiveness Network (grant number 137713).




14 August 2018


Alzheimer's Dementia (AD) is the most common cause of dementia. Patients living with AD have a lower quality of life (deterioration in memory, thinking, perception, function, behaviour, and mood) and AD ultimately leads to death. Currently, there is no cure for AD, and patients may respond differently to the medication based on their characteristics (eg, severity of disease, sex). We aim to investigate the association between the cognitive enhancers for different patient characteristics and Mini-mental State Examination or overall serious adverse events. The findings of this study will help to improve guidelines for the management of patients with AD.



[{ "PostingID": 115, "Title": "GSK-AVA102677", "Description": "An open-label extension study of the long-term safety and efficacy of rosiglitazone extended-release (RSG XR) in subjects with mild-to-moderate Alzheimer's disease (REFLECT-5)" },{ "PostingID": 116, "Title": "GSK-AVA105640", "Description": "A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer’s disease. (REFLECT-1)" },{ "PostingID": 4086, "Title": "NOVARTIS-CENA713D1301", "Description": "A 24-week, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Evaluation of the Efficacy, Safety, and Tolerability of the Once-daily Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease (MMSE 10-20)" },{ "PostingID": 4688, "Title": "NOVARTIS-CENA713D2320", "Description": "Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease" },{ "PostingID": 4689, "Title": "NOVARTIS-CENA713D2340", "Description": "A 48-Week, Multicenter, Randomized, Double-Blind, Parallel-Group Evaluation of the Com-parative Efficacy, Safety, and Tolerability of Exelon® 10 and 15 cm2 Patch in Patients with Alzheimer’s Disease Showing Cognitive Decline during an Initial Open-Label Treatment Phase" }]

Statistical Analysis Plan